Read by QxMD icon Read


Erin C Strickland, Oneka T Cummings, Ayodele A Morris, Alexandra Clinkscales, Gregory L McIntire
Treatment adherence is often an issue with mental health patients. For those prescribed quetiapine (Seroquel(®)), the low levels of parent drug and plasma metabolite(s) (e.g., 7-hydroxyquetiapine) typically used in urine drug monitoring can result in false negatives with concomitant unfavorable impacts on patient care. Literature review coupled with liquid chromatography/time-of-flight mass spectrometry analysis of patient positive urine samples indicated the presence of quetiapine carboxylic acid and quetiapine sulfoxide as significant urinary metabolites of quetiapine...
October 2016: Journal of Analytical Toxicology
Fethi Trabelsi, Negar Gharavi, Magdalene Kalovidouris, Martha Nikolaidou
OBJECTIVE: The purpose of this study was to assess bioequivalence between a generic and a brand quetiapine 400 mg prolonged-release (PR) formulation (Pharmathen S.A.; AstraZeneca Seroquel Prolong®<) in healthy volunteers under steady-state conditions. METHODS: Randomized, open-label, steady-state, 2-way crossover design in 48 subjects under fasting conditions. As a quetiapine dose of 400 mg was suspected to be high when administered to healthy subjects, we proceeded with an innovative design where subjects were titrated up using 150 mg, 200 mg, and 300 mg daily doses; first treatment (days 4 - 9) and second treatment (days 10 - 15), and then a tapering down phase (days 16 - 17)...
September 2016: International Journal of Clinical Pharmacology and Therapeutics
V Osborne, M Davies, D Layton, S A W Shakir
BACKGROUND: A post-authorisation safety study was carried out as part of the EU Risk Management Plan to examine the long-term (up to 12 months) use of quetiapine XL as prescribed in general practice in England. AIM: To present a description of the drug utilisation characteristics of quetiapine XL. METHODS: An observational, population-based cohort design using the technique of Modified Prescription-Event Monitoring (M-PEM). Patients were identified from dispensed prescriptions issued by general practitioners (GPs) for quetiapine XL between September 2008 and February 2013...
March 2016: European Psychiatry: the Journal of the Association of European Psychiatrists
Scott Monteith, Tasha Glenn, Rita Bauer, Jörn Conell, Michael Bauer
BACKGROUND: There is increasing use of online pharmacies to purchase prescription drugs. While some online pharmacies are legitimate and safe, there are many unsafe and illegal so-called "rogue" online pharmacies. This study investigated the availability of psychotropic drugs online to consumers in the US, using 5 commonly prescribed drugs for bipolar disorder. METHODS: Using the search term "buy [drug name]" in the Google, Yahoo and Bing search engines, the characteristics of the online pharmacies found on the first two pages of search results were investigated...
March 15, 2016: Journal of Affective Disorders
Ami Schattner, Ella Kitroser, Joel D Cohen
Acute psychosis developed in an elderly patient with Parkinson disease and she was admitted and treated with quetiapine (Seroquel). One day later, high fever unexplained by infection appeared associated with restlessness, confusion, convulsion, leukocytosis, and extreme serum creatine kinase levels. She died of neuroleptic malignant syndrome (NMS) despite intensive treatment. Quetiapine is an atypical neuroleptic agent, rarely associated with NMS in the absence of other contributing drugs. Our case strongly establishes quetiapine-induced NMS (Naranjo scale 6) and is also unique in the abrupt onset and severe refractory course...
September 2016: American Journal of Therapeutics
L P Smirnova, D A Parshukova, Yu N Borodyuk, E G Kornetova, G D Tkacheva, A A Seregin, T G Burdovitsina, A V Semke
OBJECTIVE: To study correlations between parameters of lipid metabolism and ECG in patients with schizophrenia in light of therapy with atypical antipsychotics. MATERIAL AND METHODS: We examined 42 patients with paranoid schizophrenia. All patients received atypical neuroleptics - seroquel, zyprexa, and rispolept. A group of controls included 25 healthy people. RESULTS: There was a significant increase (p=0.0002) in body mass (in average by 1...
2015: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
Manpreet Singh, Paul A LeLorier, Murat M Celebi, D Luke Glancy
A 90-year-old man with a history of high blood pressure, a cerebrovascular accident without focal residua, dementia, and stage 3 chronic kidney disease went to the emergency department because of dizziness and near syncope. His medications were aspirin 81 mg qd, clopidogrel 75 mg qod, escitalopram oxalate 10 mg qd, Seroquel 25 mg qd, and memantine hydrochloride 10 mg qd. He had orthostatic hypotension with supine blood pressure of 173/77 mm Hg falling to 116/68 on standing, while pulse increased from 66 to 84 beats/ min...
March 2015: Journal of the Louisiana State Medical Society: Official Organ of the Louisiana State Medical Society
Diansong Zhou, Khanh H Bui, Jianguo Li, Nidal Al-Huniti
A population model describing quetiapine pharmacokinetics (PK) in Western and Chinese patients following oral administration of immediate-release (IR) and extended-release (XR) formulations was developed using plasma concentrations in 127 patients from 5 studies with quetiapine IR and/or XR in Western patients and 1 study with quetiapine XR in Chinese patients. A 1-compartmental model with first-order absorption and first-order elimination adequately described the quetiapine PK. The typical apparent volume of distribution and elimination rate constant of quetiapine were 574 L and 0...
November 2015: Journal of Clinical Pharmacology
Piotr Kulinowski, Krzysztof Woyna-Orlewicz, Gerd-Martin Rappen, Dorota Haznar-Garbacz, Władysław P Węglarz, Przemysław P Dorożyński
Motivation for the study was the lack of dedicated and effective research and development (R&D) in vitro methods for oral, generic, modified release formulations. The purpose of the research was to assess multimodal in vitro methodology for further bioequivalence study risk minimization. Principal results of the study are as follows: (i) Pharmaceutically equivalent quetiapine fumarate extended release dosage form of Seroquel XR was developed using a quality by design/design of experiment (QbD/DoE) paradigm...
April 30, 2015: International Journal of Pharmaceutics
Andre Tapp, Amanda Ernst Wood, Annette Kennedy, Patrick Sylvers, Nael Kilzieh, Andrew J Saxon
BACKGROUND: Cocaine addiction continues to be a significant healthcare issue, yet there are no FDA approved medications for the treatment of cocaine use disorder within the United States. METHODS: This 12-week, prospective, double-blind, randomized, placebo-controlled study examined the effectiveness of quetiapine (Seroquel XR™) versus matched placebo for the treatment of DSM-IV cocaine dependence in non-psychotic individuals. Subjects randomized to quetiapine (N = 29) were titrated up to a target dose of 400mg/day of quetiapine, while those in the placebo arm (N = 31) were given a matched placebo...
April 1, 2015: Drug and Alcohol Dependence
Robert H Howland
A potential adverse effect of many non-cardiac drugs, including certain psychotropic medications, is an abnormally prolonged corrected QT (QTc) interval and an increased risk of developing torsade de pointes, a type of tachyarrhythmia associated with sudden death. A relatively recent literature review suggested that haloperidol (Haldol(®)) is more likely to cause QTc prolongation than quetiapine (Seroquel(®)). The current article critically evaluates this literature review by examining the original source studies cited by the authors to support their conclusion...
June 2014: Journal of Psychosocial Nursing and Mental Health Services
P Meats
Antipsychotic drugs are the mainstay of treatment of patients with schizophrenia. These drugs cause many side-effects, of which the most problematic are extrapyramidal symptoms. This paper reviews published preclinical and clinical studies on quetiapine, a new atypical antipsychotic. The preclinical studies predict a low risk of extrapyramidal symptoms, and this is borne out in clinical trials in patients with relapses of moderate or severe schizophrenia. Indeed, the occurrence of extrapyramidal symptoms with quetiapine is indistinguishable from that with placebo across the dose range...
1997: International Journal of Psychiatry in Clinical Practice
Suresh Chari, Ak Jainer, Andrew Ashley-Smith, Maxine Cleaver
Tardive dyskinesia (TD) is a potentially irreversible side-effect of antipsychotic medication. Some atypical antipsychotics, by virtue of their better side-effect profile, seem to have an ability to reverse TD. The importance of trying to treat TD has become more urgent in view of the medico-legal implications of Article 3 of the Human Rights Act, 1998 which states that ''no one shall be subjected to inhuman or degrading treatment or punishment'': interpretation of this article was successfully used to win a large out-of-court settlement for a patient with TD in our region...
2002: International Journal of Psychiatry in Clinical Practice
Juan Gibert, José Giner, Julio Bobes, Mónica Tafalla, Santiago Herranz, Carmen Ovejero, Fernando Rico-Villademoros, For The Sos Group 1, Juan Gibert, José Giner, Julio Bobes, Mónica Tafalla, Santiago Herranz, Carmen Ovejero, Fernando Rico-Villademoros, For The Sos Group 1
Objective. The "Seroquel" Outcomes Study (SOS) aimed to assess the efficacy and tolerability of quetiapine in patients with schizophrenia in the clinical practice setting. Methods. A 6-month, non-comparative, open-label study in adults with schizophrenia in a standard care setting in Spain. Outpatients received flexibly dosed quetiapine. Efficacy was evaluated using the Brief Psychiatry Rating Scale (BPRS) and the Clinical Global Impression (CGI) scale. BPRS response was defined as≥30% decrease from baseline...
2007: International Journal of Psychiatry in Clinical Practice
Torsten Gruettert, Lars Friege
Objective Atypical antipsychotics appear to be effective and well tolerated in the treatment of borderline personality disorder. One such agent, quetiapine ("Seroquel"), has a favourable side-effect profile and may be of value in acute and chronic treatment of this disorder. Methods In this case series, 12 outpatients with psychotic disorders meeting ICD-10, DSM-IV and DIB-R criteria for borderline personality disorder were treated with quetiapine monotherapy 300-750 mg/day. The CGI-S and the GAS assessed changes in symptom severity and global functioning, whereas the BIS, the HAM-D and the SCL-90-IX scales assessed change of psychotic symptoms and/or borderline personality disorder core symptomatology over time...
2005: International Journal of Psychiatry in Clinical Practice
Jonathan S E Hellewell
Objectives. Compared with conventional agents, atypical antipsychotics such as quetiapine (Seroquel®; AstraZeneca) show improved tolerability and a lower liability to cause extrapyramidal symptoms (EPS). In the routine treatment of schizophrenia, it is usual practice to consider a change of medication when the current treatment is ineffective or poorly tolerated, although few studies are available to guide clinicians. This paper reports the results from the Seroquel Method. Patient Evaluation on Changing Treatment Relative to Usual Medication (SPECTRUM) trial, a 12-week, open-label, noncomparative study that evaluated clinical benefit and tolerability of switching patients with schizophrenia from their existing antipsychotic to quetiapine...
2007: International Journal of Psychiatry in Clinical Practice
A De Nayer, E Windhager, Irmansyah, I Larmo, B Lindenbauer, H Rittmannsberger, T Platz, Am Jones, Jl Whiteford, Ca Altman
OBJECTIVE The Seroquel Patient Evaluation on Changing Treatment Relative to Usual Medication (SPECTRUM) study assessed the efficacy and tolerability of quetiapine (Seroquel™) in patients with schizophrenia switched from treatments providing suboptimal outcomes. METHODS This was an international, open-label, non-comparative study, designed with titration to 400 mg/day quetiapine over 7 days, then flexible dosing (300-750 mg/day) for 11 weeks. Efficacy was assessed with the Positive and Negative Syndrome Scale (PANSS); Clinical Global Impression (CGI) Severity of Illness and Global Improvement scores; and the Calgary Depression Scale for Schizophrenia (CDSS)...
2003: International Journal of Psychiatry in Clinical Practice
I Reznik R Benatov P Sirota
The recent advent of atypical antipsychotics has provided new clinical options and set higher expectations for the treatment of schizophrenia. Such agents might more effectively prevent relapse because they are more effective against the full spectrum of schizophrenic symptoms, as well as having improved tolerability and leading to improved medication compliance. Quetiapine fumarate ('Seroquel') is a new dibenzothiazepine antipsychotic agent with a greater affinity for serotonin receptors than for dopamine receptors and with a lower propensity for producing extrapyramidal symptoms or increasing prolactin levels...
2000: International Journal of Psychiatry in Clinical Practice
M Brecher, I W Rak, K Melvin, A M Jones
INTRODUCTION: Quetiapine (Seroquel TM ) is an atypical antipsychoticdrug with demonstrated efficacy and tolerability. In particular, placebo-level extrapyramidal symptoms (EPS) across the entire dose range and a low propensity to cause sexual dysfunction suggest it may be associated with greater patient acceptability than alternative treatments. However, other side-effects, such as weight gain, may also have a significant impact on treatment acceptability. METHOD: We report the long-term weight changes observed in a cohort of 427 patients with schizophrenia from controlled and open-label extension (OLE) trials, in which quetiapine (mean dose 475 mg/day after 1 year) was the only antipsychotic medication during the OLE period...
2000: International Journal of Psychiatry in Clinical Practice
Angela E McLelland, Mathew T Martin-Iverson, Richard J Beninger
RATIONALE: Recent case reports describe recreational use of quetiapine and drug-seeking behaviour to obtain quetiapine, an atypical antipsychotic. OBJECTIVE: We examined the hypothesis that quetiapine (10, 20 or 40 mg/kg) alone or co-administered with (+)-amphetamine (0.25, 0.5, 0.75 or 2.0 mg/kg) will affect reward and/or decrease anxiety in rats, as measured by conditioned place preference (CPP) and elevated plus maze (EPM) test, respectively. RESULTS: Quetiapine (20 mg/kg) produced greater open arm time and entries in the EPM test compared to 10 and 40 mg/kg, and quetiapine (10 mg/kg) significantly increased open arm entries and time when co-administered with (+)-amphetamine (0...
November 2014: Psychopharmacology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"